Encompass Diagnostics

Prospective Molecular Diagnostic Testing

We are a CLIA high-complexity molecular testing laboratory with >10 years of experience in real-time QPCR technologies/applications. We are the molecular biology experts! Every infectious disease panel will be accompanied by Antibiotic Resistance (ABR) genes. ABR genes will aid in the appropriate selection of narrow-spectrum antibiotics for treatment and promote Antibiotic Stewardship.

Molecular Testing

Encompass Diagnostics is reinventing laboratory services for healthcare providers

We believe in fast results, unbeatable accuracy, and continually building on ever-changing technologies, whether we’re battling COVID-19 or breaking down wound samples. Encompass Diagnostics is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity molecular testing and moderate complexity clinical testing. Using molecular testing, we’re able to provide a thorough breakdown of the pathogens causing an infection within 24-48 hours, making our lab reports and recommendations timely for gastrointestinal issues, women’s health, men’s health, wounds, and others. Our test panels include Wound, Nail, RPP, UTI, GI, Antibiotic resistance, COVID, and COVID with reflex to 4 variants.

Encompass Diagnostics laboratory

Innovative and Advanced

Our innovative diagnostic system can quickly find out what infection is present and how much of each exists. By extracting the sample’s DNA and immediately processing it, we’re able to see exactly what the sample is made up of and break it down into percentages. No need to wait for samples to grow or test resistance to occur. This is all a same-day procedure.


Encompass Diagnostics was formed with one specific purpose: to impact and improve lives by empowering patients and their physicians with the information needed to improve their health. Our scientists and researchers work tirelessly to advance one of the most important developments in the history of medicine, Molecular Diagnostic Testing, allowing healthcare professionals to quickly diagnose and treat conditions with improved safety and accuracy. Our services include molecular pathogen testing, pharmacogenetics, and other specialty molecular testing. Encompass Diagnostics also provides high capacity COVID-19 testing for individuals and workplace environments nationwide.

Trust Encompass Diagnostics With Your Molecular Pathogen Diagnostics

Molecular pathogen diagnostics has been a core focus of Encompass Diagnostics for years and has led to faster and more accurate diagnoses for patients when compared with traditional culture testing. We work with many facilities that depend on Encompass Diagnostics for the accuracy and specificity needed to maintain optimal health.

The value of molecular testing

Detection


Encompass Diagnostics can detect more than 30 different types of wound pathogens and deliver 99% accurate results within 24-48 hours of lab sample receipt.

Accuracy


Encompass Diagnostics molecular pathogen testing is more accurate than standard culture testing. Our molecular pathogen testing detects anaerobic organisms growing deep inside a wound that standard cultures often miss.

Amplification


Using a molecular approach, amplification of testing sample genetic material is faster than standard culture growth and delivers increased sensitivity and a quicker result.

Speed


Our rapid TAT is within 24-48 hours from laboratory receipt.

Simplicity


Our simple to read report gives clinicians quick, actionable intelligence to make better treatment decisions

Identification


Ability to identify pathogens when the patient is on empiric antibiotic therapy

With molecular testing, not only can you receive a clear picture of the type and percent of pathogens causing the infection. In many cases, you can identify antimicrobial resistance. With the power of molecular testing, you can select the optimal drug therapy for your patient, improve treatment outcomes and reduce healthcare spend.

The Encompass Diagnostics molecular panel includes the following test types:

  • Respiratory Infections
  • Urinary Tract Infection
  • Gastrointestinal Infections
  • Genitourinary Infections Women's Health and STI
  • Wound Infections
  • Fungal Nail Infection
  • COVID-19 / FLU / RSV
  • Vaginitis

For a full list of pathogens tested, please visit encompassdiagnostics.com

Molecular tests can be covered by Medicare and Medicaid. Commercial coverage will vary based upon geography and plan type, and typically requires prior authorization.

Encompass Diagnostics Molecular PCR tests:

  • Detect 30 pathogens (bacterial/fungal)
  • Detect pathogens that may not be detectable in culture
  • Identify 9 classes of antibiotic resistance markers
  • Are unaffected by concurrent antibiotic use
  • Provide an accurate diagnosis within 48 hours

Encompass Diagnostics provides a full range of molecular and clinical diagnostic testing including the following:

  • Women’s Health Pathogen Panel
  • GI Pathogen Panel
  • COVID-19 Diagnostic Testing
  • Nail Pathogen Panel
  • UTI Pathogen Panel
  • Wound Pathogen Panel
  • FLU A/B with RSV Panel
  • Respiratory Pathogen Panel
  • COVID-19 Antibody Testing

These comprehensive diagnostic tests are covered by most insurance carriers

  • Encompass Diagnostics has flexible lab capacity to meet your needs as they change.
  • Encompass Diagnostics offers high complexity molecular testing options not available at many laboratories.
  • Encompass Diagnostics provides a dedicated service manager to help manage your relationship with our lab.

Nail and Wound Infections

Detection, Diagnosis and Treatment Designed for Senior Living Residents


Encompass Diagnostics offers molecular PCR tests to identify Nail and Wound Infections

According to the National Institutes of Health, about 6.7 million people in the U.S. are affected by chronic wounds. Residents with infected wounds can experience an abnormal healing process that may lead to longer-term care, additional medications, pain, stress, depression, hospitalization, function and mobility loss. The result is higher costs for healthcare organizations and residents alike.

Encompass Diagnostics combines advancements in molecular diagnostics and drug efficacy data, then puts that information into actionable resident-centered reports.

Clinician treating a nail infection

Molecular PCR tests for nail and wound infections can identify:

  • Bacterial and fungal pathogens
  • Quantitative values of each specific pathogen, unaffected by concurrent antibiotic use?
  • Bacterial resistance pathways and antibiotic classes
  • Detection of polymicrobial infections

With Encompass Diagnostics, you will receive therapeutic options for your residents based on effective medications for the positively identified pathogens cross-referenced with the antibiotic resistant markers. The result is a reduction in unnecessary medication exposure and adverse events.

Gastrointestinal Infections

Reduce unnecessary testing, improve resident satisfaction with the Encompass Diagnostics molecular PCR GI panel.


Gastrointestinal system

Molecular PCR testing is more accurate than standard culture and sensitivity testing, identifying – with 99% accuracy-all bacteria, viruses, parasites, and H Pylori with antimicrobial resistance. These tests can identify pathogens with 99% accuracy, even when the resident is on empiric antibiotic therapy.

Encompass Diagnostics combines advancements in molecular diagnostics and drug efficacy data into actionable patient-centered information to help physicians determine the most appropriate treatment regimen for each resident.

Sample Collection Made Easy

With the Encompass Diagnostics GI test, the sample is collected with a fecal swab, eliminating the need to ship a raw specimen.

Results are delivered 24-48 hours from laboratory receipt of the sample and our simple-to-read report gives clinicians quick, actionable intelligence to make better treatment decisions.1 The report includes therapeutic options for your residents that are based on effective medications for the positively identified pathogens, cross-referenced with the antibiotic resistant markers, This reduces unnecessary medication exposure and adverse events.

Urinary Tract Infection (UTI)

In nursing homes, as many as two thirds of residents receive antibiotics each year and up to 75% of these are estimated to be inappropriate.


The Encompass Diagnostics Molecular PCR UTI Test is the Solution

The prevalence of UTI infections means that advanced diagnostics are critical for rapidly and accurately identifying the pathogens causing the infection. Improper diagnosis or treatment can lead to ongoing pain and discomfort, chronic infections, permanent kidney damage and life-threatening sepsis.2 Provide your residents with the Encompass Diagnostics Molecular PCR UTI test to treat UTIs effectively and safely, eliminating false negative and false positive results.

Female and male urinary tract

The benefits of the Encompass Diagnostics PCR test include:

  • Identification of the combinations of pathogens (viruses, bacteria, and fungi) causing the infection as well as the detection of antibiotic resistance3
  • Results that are unaffected by concurrent antibiotic use at the time of the test
  • The ability to collect the urine sample via brief swab as well as a clean catch

With the power of molecular testing, you can select the optimal therapy for your residents, improve treatment outcomes and reduce healthcare spend.

Molecular Diagnostics Testing

Bacterial

  • Acinetobacter baumannii
  • Enterobacter cloacae complex, Klebsiella
  • (Enterobacter) aerogenes
  • Escherichia coli
  • Haemophilus influenzae
  • Klebsiella pneumoniae, oxytoca
  • Moraxella catarrhalis
  • Proteus mirabilis, vulgaris
  • Pseudomonas aeruginosa
  • Serratia marcescens
  • Staphylococcus aureus
  • Streptococcus agalactiae (Group B Strep)
  • Streptococcus pneumoniae
  • Streptococcus pyogenes (Group A Strep)

Atypical Bacteria

  • Bordetella pertussis, parapertussis, bronchiseptica
  • Chlamydia pneumoniae
  • Legionella pneumophila
  • Mycoplasma pneumoniae

Viral

  • Adenovirus
  • Coronaviruses (229E, HKU1, NL63, & OC43)
  • COVID-19 Coronavirus (SARS-CoV-2)
  • Enterovirus D68
  • Human metapneumovirus
  • Influenza virus A, B
  • Parainfluenza virus (types 1, 2, 3, 4)
  • Respiratory syncytial virus
  • Rhinovirus/Enterovirus

Resistance

  • ACT, MIR, FOX, ACC Groups
  • CTX-M1 (15), M2 (2), M9 (9), M8/25 Groups
  • dfr (A1, A5), sul (1, 2)
  • ermB, C; mefA
  • IMP, NDM, VIM Groups
  • mecA
  • OXA-48, OXA-51
  • qnrA1, A2, B2
  • SHV, KPC Groups
  • tet B, tet M

Encompass Diagnostics is certified according to the Clinical Laboratory Improvement Amendment of 1988 (CLIA) for high complexity molecular testing and moderate complexity clinical testing.

Clinical Laboratory Improvement Amendments